A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
ConditionEarly Alzheimer's Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50-85
SponsorMerck Sharp & Dohme LLC
About this trial
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.
The goals of the study are to learn:
* If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it
Eligibility criteria
Qualifiers
Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
Has a designated study partner who can fulfill the requirements of this study
If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening
Disqualifiers
Has a known history of stroke or cerebrovascular disease
Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
Has structural brain disease
Has a history of seizures or epilepsy within 5 years before screening
Trial design
Treatments tested in this trial
- MK-2214
- Placebo
Treatment groups
340 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov